Objective: To evaluate the value of exhaled nitric oxide concentration in the treatment of cough variant asthma in children, treated with glucocorticoids combined with leukotriene receptor antagonists. Methods: A total of 156 children diagnosed definitely cough variant asthma were randomly divided into the experimental group and the control group (n=78 for each group). The experimental group was treated with a combination of glucocorticoids and leukotriene receptor antagonists, while the control group was treated with glucocorticoids alone. The aim was to observe the clinical efficacy, pulmonary function, inflammatory factor expression level, and adverse reactions between the two groups, analyzing the relationship between FeNO concentration and FEV1%pred. Results: There were statistically significant differences in clinical efficacy, clinical symptom relief time, pulmonary function, and expression of inflammatory factors between the experimental group and the control group (P<0.05). However, there was no significant difference in adverse reactions between the two groups (P>0.05). There was a significant negative correlation between FeNO concentration and FEV1%pred (r=−0.9491, 95%CI: −0.9627 to −0.9307, P<0.001), and there was also a significant negative correlation between FeNO concentration and PAQLQ score (r=−0.9313, 95%CI: −0.9495 to −0.9069, P<0.001). The ROC curve of FeNO to FEV1%pred illustrated that: AUC=0.807, 95%CI: 0.735 to 0.878, P<0.001. Youden index=0.633. The best cutoff value for FeNO diagnosing CVA is at 40.5 μg/L, with 90% sensitivity, 73.3% specificity, 93.6% positive predictive value, and 62.9% negative predictive value. Conclusion: Glucocorticoids combined with leukotriene receptor antagonists have a significant effect on the treatment of cough variant asthma in children. Monitoring FeNO concentration, before and after treatment, can evaluate properly the improvement of lung function.